Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial

OBJECTIVE: In SILIUS (NCT01214343), combination of sorafenib and hepatic arterial infusion chemotherapy did not significantly improve overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) compared with sorafenib alone. In this study, we explored the relationship between obje...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Liver Cancer
Main Authors: Kudo, Masatoshi, Ueshima, Kazuomi, Chiba, Yasutaka, Ogasawara, Sadahisa, Obi, Shuntaro, Izumi, Namiki, Aikata, Hiroshi, Nagano, Hiroaki, Hatano, Etsuro, Sasaki, Yutaka, Hino, Keisuke, Kumada, Takashi, Yamamoto, Kazuhide, Imai, Yasuharu, Iwadou, Shouta, Ogawa, Chikara, Okusaka, Takuji, Kanai, Fumihiko, Arai, Yasuaki
Formato: Artigo
Idioma:Inglês
Publicado em: S. Karger AG 2019
Assuntos:
Original Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6883462/
https://ncbi.nlm.nih.gov/pubmed/31799207
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000503032
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados